Healthcare Groups Praise Unanimous Committee Approval Of MA Prior Auth Bill
The House Ways and Means Committee unanimously advanced a bill to reform Medicare Advantage prior authorization requirements.
The House Ways and Means Committee unanimously advanced a bill to reform Medicare Advantage prior authorization requirements.
The Coalition Against Surprise Medical Billing launched a campaign opposing the No Surprises Act Enforcement Act, arguing it would worsen IDR process abuse.
Grounded in authoritative content and verified at every step, Protégé is the only legal AI tool that delivers work you can trust—without exception.
Nearly 200 healthcare and patient advocacy organizations endorsed the bipartisan Clinical Trial Modernization Act, which seeks to reduce financial barriers and expand access to clinical trials for underrepresented patients.
A former Mayo Clinic research director claims she was silenced, demoted, and ultimately fired for sounding the alarm on AI safety and patient privacy lapses at the health system. Traci Tamiko Eto is now suing Mayo for retaliation.
Elevance alleges that CMS unlawfully refused to recalculate its 2026 Medicare Advantage Star Ratings on the same basis that it recently recalculated Clover Health's ratings after a court ruling.
A new report finds private equity firms are increasingly using joint ventures with nonprofit health systems to expand in healthcare, prompting calls for greater oversight.
LexisNexis sat down with John Ursin, Managing Partner at Schenck Price, to learn how the firm is using legal AI to strengthen client service and daily legal work.
Debunked Podcast co-hosts Arundhati Parmar and Samir Batra discussed some of the takeaways from UnitedHealth Group’s press event, transparency, and pharma company Lilly’s efforts to hold hospitals accountable in the 340B drug discount program
A 'cynical optimist' breaks down how law impacts the healthcare you receive.
The Medicare Cost Cap Act seeks to create a $5,000 cap on out-of-pocket costs for traditional Medicare beneficiaries.
Congressional Democrats are seeking to repeal the controversial WISeR model, but experts are unsure if their efforts will succeed.
Once you’ve got your law degree, how do you keep your professional skills up to date? Share your perspective in this brief survey, and you may be eligible to win a $250 gift card.
This gene therapy is the latest in a growing list of rare disease treatments to receive reconsideration from an FDA that appears to be swinging back to regulatory flexibility.
FDA concerns about Amgen’s Tavneos were sparked by securities fraud litigation against ChemoCentryx, the company that originally developed the rare disease drug. The FDA wants to withdraw Tavneos’s approval, citing safety risks and alleged manipulation of the drug’s clinical trial data.
One Nation, Overcharged, a campaign backed by the Robert Wood Johnson Foundation, launched to raise awareness of rising healthcare costs.
Rick Pazdur, formerly the FDA’s top oncology official, said the FDA is at a critical juncture that could determine the direction of the world’s top regulator of medicines.
Provider groups largely welcomed the reforms — though some industry leaders said additional changes are still needed to address alleged misuse and improve transparency.